Syndax Pharmaceuticals Inc (SNDX)
20.73
-0.54
(-2.54%)
USD |
NASDAQ |
Apr 17, 16:00
20.73
0.00 (0.00%)
After-Hours: 20:00
Syndax Pharmaceuticals Cash from Financing (TTM): 264.13M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 264.13M |
September 30, 2023 | 169.15M |
June 30, 2023 | 153.78M |
March 31, 2023 | 174.17M |
December 31, 2022 | 172.25M |
September 30, 2022 | 118.53M |
June 30, 2022 | 133.76M |
March 31, 2022 | 118.06M |
December 31, 2021 | 118.46M |
September 30, 2021 | 147.34M |
June 30, 2021 | 147.40M |
March 31, 2021 | 250.39M |
December 31, 2020 | 304.42M |
September 30, 2020 | 165.82M |
June 30, 2020 | 164.14M |
March 31, 2020 | 55.14M |
December 31, 2019 | 28.57M |
September 30, 2019 | 34.66M |
June 30, 2019 | 44.04M |
March 31, 2019 | 44.12M |
December 31, 2018 | 15.73M |
Date | Value |
---|---|
September 30, 2018 | 35.20M |
June 30, 2018 | 26.74M |
March 31, 2018 | 75.64M |
December 31, 2017 | 75.72M |
September 30, 2017 | 50.28M |
June 30, 2017 | 50.99M |
March 31, 2017 | 0.771M |
December 31, 2016 | 54.20M |
September 30, 2016 | 44.84M |
June 30, 2016 | 103.19M |
March 31, 2016 | 123.10M |
December 31, 2015 | 77.27M |
September 30, 2015 | 90.44M |
June 30, 2015 | 39.90M |
March 31, 2015 | 20.33M |
December 31, 2014 | 12.41M |
September 30, 2014 | 20.29M |
June 30, 2014 | 17.25M |
March 31, 2014 | 19.15M |
December 31, 2013 | 20.89M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
28.57M
Minimum
Dec 2019
304.42M
Maximum
Dec 2020
145.49M
Average
147.40M
Median
Jun 2021
Cash from Financing (TTM) Benchmarks
SpringWorks Therapeutics Inc | 296.64M |
Alnylam Pharmaceuticals Inc | 172.13M |
Geron Corp | 362.02M |
Ionis Pharmaceuticals Inc | 644.08M |
Madrigal Pharmaceuticals Inc | 595.12M |